Cone-beam CT guided Stereotactic Radiation Therapy for Locally Advanced and Locally Recurrent Pancreatic Cancer

Cone-beam CT guided Stereotactic Radiation Therapy for Locally Advanced and Locally Recurrent Pancreatic Cancer - SBRT for pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON43956

Enrollment

Registered

2013-05-15

Start date

2013-07-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Pre-treatment, (recurrent) pancreatic cancer has to be pathology proven. Patients will undergo a contrast-enhanced CT scan, a contrast-enhanced MRI scan, endoscopic fiducial placement, and patients

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Pancreatic cancer: - Primary unresectable pancreatic tumors according to Dutch Pancreatic Cancer Group; or - Medically inoperable patients with pancreatic cancer; or - Isolated locally recurrent pancreatic cancer. * *18 years. * Written informed consent.

Exclusion criteria

Exclusion criteria: * Evidence of distant metastasis. * WHO performance status 3-4. * Expected life span

Design outcomes

Primary

Measure	Time frame
The main study endpoint will be safety of the procedure, expressed in proportion of patients experiencing treatment-induced toxicity grade 3 or more according to the CTC-AE 4.0 due to the complete procedure within 90 days of the last irradiation.	—

Secondary

Measure	Time frame
Other study parameters will be technical feasibility, treatment response, quality of life, overall survival, progression free survival, and rate of possible secondary resections.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)